Synthesis and in vitro drug release studies on substituted polyphosphazene conjugates of lumefantrine.

Sahil Kumar, Alka Sharma, Rajesh K Singh, DN Prasad, TR Bhardwaj



The present study pertains to the delivery of antimalarial drug (Lumifantrine). In this, polyphosphazene has been used in the synthesis of polyphosphazene-linked conjugates of Lumifantrine. These polymer-linked Conjugates have been synthesized and characterized by modern analytical techniques. The in-vitro drug release of Lumifantrine drug conjugates: p-Amino benzoic acid ester substituted polyphosphazene drug conjugate (15) and Glycine methyl ester substituted polyphosphazene drug conjugate (21) have been found to be 6.00 % and 5.96% (pH 1.2), 88.52% and 79.86% (pH 7.4), respectively. These drug conjugate may prove an effective delivery system for the treatment of malaria.


polyphosphazene, lumefantrine, conjugate, malaria, p-amino benzoic acid ester.

Full Text:



[1]. World health organization. The World Health Report. Conquering, Suffering, Enriching Humanity. Geneva; World Health Organisation Publisher; 1997.

[2]. Ashley E, Gready RM, Proux F. Malaria. Travel Med.Infect.Dis.2006; 11:159.

[3]. Lalloo DG. Malaria in adolescence: burden of disease, consequences and opportunities for intervention. Lancet Infect. Dis.2006;6:780.

[4]. Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol. 2001; 17: 593.

[5]. Breman JG. The ears of the hippopotamus:manifestations,determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 2001; 64:1.

[6]. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect. Des. 2002; 2: 209.

[7]. White NJ. Antimalarial drug resistance: the pace quickens. J Antimicrob. Chemother. 1992; 30: 571.

[8]. Foley M, Tilley L. Home improvements: malaria and the red cell. Parasitol Today. 1995; 11: 436-9.

[9]. Grau GE, De Kossodo S. Cerebral malaria: mediators, mechanical obstruction or more? Parasitol Today. 1994; 10: 408-9.

[10]. Saini S, Singh G, Kalara N, Singh CG, Virmani T. Development of nanostructured liquid crystalline formulation of antimalarial agents artemether and lumifantrine. World Journal of pharmaceutical research. 2015;4.

[11]. Liebig J, Wohler F. Justus Leibigs Ann. Chem. 1834;11:139.

[12]. Lakshmi S, Katti DS, Laurencin CT. Adv. Drug. Deliv. Rev. 2003; 55:467.

[13]. Song SC, Sohn YSJ. Control. Rel. 1998;55:161.

[14]. Schacht E, Vandrope J, Lemmouchi Y, Dejardin S, Seymour L. Frontiers in Biomed. Polym. Appl. Technomic Publishing Co. Inc. Lancaster. 1998; 27.

[15]. Gleria M. Chem. Ind.1988; 70: 15.

[16]. Shriver DFM, Tonge JS, Barriola A, Allcock HR, Blonsky PM. Polym. Prepr. 1987; 28: 438.

[17]. Allcock HR. Macromolecules.1979; 12: 1130.

[18]. Sohan YS, Cho YS, Baek H, Jung. Synthesis and properties of low molecular weight Polyphosphazenes macromolecules. 1995; 28: 7566-7568.

[19]. Mann FG, Saunders BC. Practical organic chemictry. Pearson education limited. 1973; 244-245.

[20]. Dahiya A. Synthesis, characterization and biological evaluation of a glycine-richpeptide-cherimolacyclopeptide. J. Chil. Chem. Soc. 2007; 52: 3.

[21]. Spezzacatena C, Perri T, Guantieri V, Sandberg L.B, Mitts T.F, Tamburro A.M, et al. Eur. J. Org. Chem. 2002; 1: 95.


  • There are currently no refbacks.

Copyright (c) 2017 Sahil Kumar, Alka Sharma, Rajesh K Singh, DN Prasad, TR Bhardwaj

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

               AR Journals

18K, Street 1st, Gaytri Vihar, Pinto Park, Gwalior, M.P. India (Design) 2009-2021


Follow @arjournals on Twitter